# US 2024/0197847 A1 · Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197847 A1
- Document ID: US20240197847A1
- Status: Published application
- Kind: A1
- Application number: 18/398,273
- Filed: 2023-12-28
- Published: 2024-06-20
- Earliest claimed: 2021-07-05
- Assignees: Institute of Zoology, Guangdong Academy of Sciences
- Applicants: Institute of Zoology, Guangdong Academy of Sciences
- Inventors: YUNXIAO SUN; JUNHUA RAO; DAINAN CAO; ZHEN PENG; LIBIAO ZHANG; BIHAI LI; XIANGYANG HE; FANG JI
- Web page: https://patentgrep.com/patent/US20240197847A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/35: from Mycobacteriaceae (F)
- C07K 14/47: from mammals
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 2039/543: {intranasal}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/6043: {Heat shock proteins}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention discloses a recombinant protein capable of resisting multiple sclerosis and a preparation method and application thereof, and belongs to the technical field of biopharmacy. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and 6-segment tandem repeat myelin oligodendroglia glycoprotein antigen epitope polypeptides with multiple sclerosis autoimmune antigen characteristics at the 33rd-55th sites. The recombinant protein capable of resisting multiple sclerosis is used for preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs. The present invention can play a role in preventing multiple sclerosis and can avoid side effects caused by most of disease modifying therapy (DMT) drugs.

## Claims

### Claim 1

A recombinant protein capable of resisting multiple sclerosis, comprising HSP65 protein and antigen epitope polypeptide MOG35-55, wherein the recombinant protein comprises an HSP65 protein and 6-segment tandem repeat antigen epitope polypeptide MOG35-55, i.e., the recombinant protein comprises HSP65 and 6MOG35-55, and wherein the HSP65 protein and the 6-segment antigen epitope polypeptide MOG35-55 are connected through an Ala-Ser-Ala flexible joint and wherein a sequence of the recombinant protein is SEQ ID NO.1.

### Claim 2 (depends on 1)

A preparation method of the recombinant protein capable of resisting multiple sclerosis, which is used for preparing the recombinant protein capable of resisting multiple sclerosis of claim 1, comprising the following steps:
(1) building a recombinant plasmid pET28a-His-HSP65-6MOG35-55 to obtain engineering bacteria having the recombinant plasmid;
(2) culturing the engineering bacteria with an LB culture medium; when the bacteria reach a logarithmic growth period, adding a sterile lactose solution of 0.5 mol/L into the culture medium until a final concentration is 5 mmol/L; and after further culture for 7 hours, collecting the bacteria;
(3) separating fusion protein and purifying the fusion protein by the collected bacteria to obtain the recombinant protein capable of resisting multiple sclerosis.

### Claim 3 (depends on 2)

The preparation method of the recombinant protein capable of resisting multiple sclerosis of claim 2, wherein the step (1) comprises the following steps:
inserting the 6MOG35-55 into pET-28a(+) to obtain the plasmid pET28a-6MOG35-55;
conducting PCR amplification on a template of the plasmid pET28a-6MOG35-55 to obtain a target gene segment for encoding 6MOG35-55 sequence;
conducting NheI and HindIII double digestion on a pET28a-His-HSP65-6P277 vector to obtain a linearized cloning vector;
recombining the target gene segment for encoding 6MOG35-55 sequence and the linearized cloning vector to obtain the recombinant plasmid; transforming the recombinant plasmid into a competent cell and selecting a positive clone by PCR; and verifying the obtained positive clone to finally obtain the engineering bacteria having the recombinant plasmid.

### Claim 4 (depends on 2)

The preparation method of the recombinant protein capable of resisting multiple sclerosis of claim 2, wherein in the step (3):
lysing the collected bacteria and ultrasonically breaking the bacteria on ice; analyzing the supernatant and precipitate respectively and determining that the fusion protein is an inclusion body;
processing the inclusion body with an inclusion body solution containing urea; collecting the supernatant; and purifying the target protein with Ni-NTA agarose gel column to obtain the recombinant protein His-HSP65-6MOG35-55.

### Claim 5 (depends on 1)

An application of the recombinant protein capable of resisting multiple sclerosis of claim 1 in preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs.

### Claim 6 (depends on 5)

The application of the recombinant protein capable of resisting multiple sclerosis of claim 5, wherein the multiple sclerosis vaccines or multiple sclerosis drugs are administered intranasally.
